Chimerix (NASDAQ:CMRX – Get Free Report) posted its earnings results on Wednesday. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.04), Zacks reports. Chimerix had a negative return on equity of 39.62% and a negative net margin of 25,337.96%. During the same quarter last […]
Chimerix, Inc. (NASDAQ:CMRX – Get Free Report) was the target of a significant decrease in short interest in January. As of January 15th, there was short interest totalling 1,140,000 shares, a decrease of 7.3% from the December 31st total of 1,230,000 shares. Currently, 1.4% of the company’s stock are sold short. Based on an average […]
Chimerix, Inc. (NASDAQ:CMRX – Get Free Report) was the recipient of a significant decline in short interest in the month of December. As of December 15th, there was short interest totalling 1,360,000 shares, a decline of 14.5% from the November 30th total of 1,590,000 shares. Based on an average daily volume of 423,800 shares, the […]